BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05771428 (ABBV-552 in Mild Alzheimer's Disease): BVCT ex-ante prediction vs. reported outcome

On 9 Aug 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 26 Sep 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05771428
Acronym
Abroad
Drug Name
ABBV-552
Drug MoA
SV2A inhibitory modulator
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Mild Alzheimer's Disease
Human Patients
263
Sponsor
AbbVie
Phase
Phase 2

Prediction of , index 1737

Prospective Prediction
Prediction Index
1737
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in ADAS-COG14 inferior to lecanemab)
Technical Prediction
FAILURE (statistically insignificant clinical benefit in ADAS-COG14 against placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
413 days in advance
Readout Data Interpretation
ABBV-552 failed to meet the primary endpoint of ADAS-Cog14 compared with placebo (P>0.65)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants With Mild Alzheimer's Disease
Phase
Phase 2
Status
Completed
Enrollment
263
Lead sponsor
AbbVie
Conditions
Alzheimer's Disease (AD)
Interventions
DRUG: ABBV-552; DRUG: Placebo for ABBV-552
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-06-05
Primary completion
2024-08-06
Completion
2024-09-12
Results first posted
2025-10-15
Primary outcomes
  • Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 (Week 12)

NCT05771428 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials